MedTrace Logo

Study of Cardiac PET/CT Imaging to Guide Ablation Treatment of Ventricular Tachycardia

NCT02962076 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2024-12-24

Study results available
· View outcomes & findings →

Summary

Imaging is to be performed prior to procedure using positron emission tomography/ computed tomography (PET/CT), after a special dye is injected. The scans are going to be merged with other cardiac scans when doing the ablation procedure to correlate anatomy with physiology.

Conditions

  • Ventricular Tachycardia

Interventions

DRUG

[C-11] Meta-hydroxyephedrine radioactive tracer (MHED)

this tracer detects the distribution of sympathetic nerve fibers in the left ventricle

Sponsors & Collaborators

  • Biosense Webster, Inc.

    collaborator INDUSTRY

  • Washington University School of Medicine

    collaborator OTHER

  • Khaled Awad, MD

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-21
Primary Completion
2023-03-01
Completion
2024-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02962076 on ClinicalTrials.gov